{"id":"W4404736942","doi":"10.1200/jco-24-01326","title":"First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Defence and Security Accelerator; Genentech; LEO Pharma; PharmaMar; Astellas Pharma; Novo Nordisk; Eisai; Seagen; Ipsen; BeiGene; Clovis Oncology; Fujirebio US; Regeneron Pharmaceuticals; National Cancer Institute; Genomic Health; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Hazard ratio; Lenvatinib; Internal medicine; Pembrolizumab; Oncology; Carboplatin; Population; Chemotherapy; Cancer; Cisplatin; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002799862,0.001688964,0.002923586,0.000458169,0.0005234069,0.001112635,0.001056168,0.001926125,0.00704867],"category_scores_gemma":[0.00242306,0.000753477,0.001623775,0.0003987755,0.001254093,0.001129708,0.0004884208,0.003002959,0.001181226],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008726062,"about_ca_system_score_gemma":0.001456762,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004451978,"about_ca_topic_score_gemma":0.001592918,"domain_scores_codex":[0.9988812,0.0006665767,0.00006833665,0.0001700781,0.00008502816,0.0001287697],"domain_scores_gemma":[0.9989034,0.0002978036,0.0002236186,0.0001091129,0.00006875405,0.0003973281],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9670519,0.01409393,0.0004206692,0.0004739247,0.0005410617,0.00003315951,0.0000440041,0.0003090425,0.002922259,0.00009005406,0.0006616318,0.01335841],"study_design_scores_gemma":[0.9417627,0.05627212,0.0005774527,0.00001985581,0.0002212063,0.00002408748,0.00001097166,0.0002082421,0.0002523955,0.0001041417,0.0005401615,0.000006708144],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9676949,0.006885543,0.001430987,0.00132125,0.0008537876,0.01614296,0.00218837,0.0001922926,0.003289989],"genre_scores_gemma":[0.9589609,0.004486063,0.004734818,0.002512096,0.001007886,0.02125899,0.001706486,0.00004322935,0.005289522],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00704867,"threshold_uncertainty_score":0.02358013,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2458683509011842,"score_gpt":0.5513984472239566,"score_spread":0.3055300963227724,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}